ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,326.30
-0.57%
S&P ASX All Technology
3,878.80
-0.45%
Brent Oil
73.335
0.34%
US Dollar vs AUD
1.5361
0.45%
Bitcoin
93,518.41
1.27%
Pepperstone
Advertisement
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Europe
  5. EU

  6. Cellectis Nom Eo 05 (ALCLS) Share Price

Cellectis Nom Eo 05

Cellectis Nom Eo 05 (ALCLS)

EU
1.778
-0.002
( -0.11% )
Updated: 20:55:19
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
1.778
Bid
1.778
Offer
1.786
Volume
1,767
1.778 Day's Range 1.794
1.634 52 Week Range 3.44
Market Cap
81.566M
Previous Close
1.78
Open
1.79
Last Trade
12
@
1.778
Last Trade Time
20:55:19
Financial Volume
-
VWAP
-
Average Volume (3m)
35,425
Shares Outstanding
45,874,895
Dividend Yield
-
PE Ratio
-0.81
Earnings Per Share (EPS)
-2.2
Revenue
9.24M
Net Profit
-101.06M

About Cellectis Nom Eo 05

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.cellectis.com
Headquarters
Paris, Paris, Fra
Founded
-
Cellectis Nom Eo 05 is listed in the Pharmaceutical Preparations sector of the Euronext with ticker ALCLS. The last closing price for Cellectis Nom Eo 05 was 1.78 €. Over the last year, Cellectis Nom Eo 05 shares have traded in a share price range of 1.634 € to 3.44 €.

Cellectis Nom Eo 05 currently has 45,874,895 shares in issue. The market capitalisation of Cellectis Nom Eo 05 is 81.66 € million. Cellectis Nom Eo 05 has a price to earnings ratio (PE ratio) of -0.81.

Ask ADVFN Intelligence (AI)

ALCLS Latest News

More News

Monthly information on share capital and company voting rights

Monthly information on share capital and company voting rights (Article 223-16 of General Regulation of the French financial markets authority)PARIS, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Listing...

07 November 2024
UK Regulatory

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers)PARIS, 06 nov...

07 November 2024
UK Regulatory

Cellectis présente de multiples stratégies pour améliorer l'efficacité des cellules CAR T dans les tumeurs solides à la réunion annuelle de la SITC

Cellectis présente de multiples stratégies pour améliorer l'efficacité des cellules CAR T dans les tumeurs solides à la réunion annuelle de la SITC NEW YORK, 05 nov. 2024 (GLOBE NEWSWIRE...

06 November 2024
UK Regulatory

Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting

NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) --  Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform...

06 November 2024
GlobeNewswire Inc.

Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting

Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) --  Cellectis (the “Company”) (Euronext...

06 November 2024
UK Regulatory

Cellectis présente ses résultats financiers du troisième trimestre 2024 et une mise à jour de ses activités

Cellectis présente ses résultats financiers du troisième trimestre 2024 et une mise à jour de ses activités UCART22 et UCART20x22 : recrutement de patients en cours, un ensemble de données de la...

05 November 2024
UK Regulatory

Cellectis Provides Business Updates and Financial Results for Third Quarter 2024

Cellectis Provides Business Updates and Financial Results for Third Quarter 2024 UCART22 and UCART20x22: enrollment ongoing, Phase 1 dataset and late-stage development strategy to be presented in...

05 November 2024
UK Regulatory

Cellectis Provides Business Updates and Financial Results for Third Quarter 2024

UCART22 and UCART20x22: enrollment ongoing, Phase 1 dataset and late-stage development strategy to be presented in 2025AstraZeneca partnership: R&D activities are ongoing on three programs –...

05 November 2024
GlobeNewswire Inc.

Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024

Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024 NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) --  Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a...

31 October 2024
UK Regulatory

Cellectis publiera ses résultats financiers du troisième trimestre 2024 le 4 novembre 2024

Cellectis publiera ses résultats financiers du troisième trimestre 2024 le 4 novembre 2024 NEW YORK, 30 oct. 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société...

31 October 2024
UK Regulatory
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.03-1.65929203541.8081.821.702312671.76048841DE
40.0020.1126126126131.7761.871.662363771.72839375DE
12-0.332-15.73459715642.112.1351.662354251.86961321DE
26-0.952-34.87179487182.732.731.634552071.95294784DE
52-0.852-32.39543726242.633.441.634987742.47455349DE
156-6.082-77.37913486017.868.4150.8881614673.00280904DE
260-10.182-85.133779264211.9628.450.8881417186.6037158DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ALNEVNeovacs
0.0003 €
(50.00%)
7.34M
HYLHyloris Pharmaceuticals SA
4.71 €
(17.75%)
21.14k
ALSAFSAFE
0.0998 €
(17.41%)
48.13k
ALAGOEPango SA
0.12 €
(13.21%)
4.95M
ALBDMBD Multi-Media
1.40 €
(8.95%)
210
EMGDSEuromedis DS
0.0002 €
(-98.28%)
33
ALCYBCybergun
0.0001 €
(-50.00%)
2.59M
ELIORElior Group
3.298 €
(-19.87%)
3.52M
ALEMSEuropean Medical Solutions
0.0162 €
(-14.74%)
34.08k
ALSPWSpineway
0.088 €
(-13.39%)
1.57M
ALNEVNeovacs
0.0003 €
(50.00%)
7.34M
BCPBanco Comercial Portugues SA
0.4429 €
(0.70%)
6.82M
ATODSAtos SE
0.0043 €
(-12.24%)
5.67M
ALAGOEPango SA
0.12 €
(13.21%)
4.95M
ALRPDRapid Nutrition
0.054 €
(6.72%)
3.53M

Discussion

View Full Feed
Konaploinks Konaploinks 3 minutes ago
From chat gpt

Yes, IonQ and NVIDIA have recently demonstrated significant advancements in simulating molecular behaviors using hybrid quantum-classical approaches. IonQ has integrated its quantum computing capabilities with NVIDIA’s CUDA-Q platform to enhance the accuracy and efficie
IONQ
Investor Will Investor Will 6 minutes ago
For some reason the link simply returns to the post.
MrLWLG101 MrLWLG101 7 minutes ago
What frequencies are necessary, then? The fact is that it is not yet known that these packages are being offered. This will likely be covered under the NDA for the entire chain
LWLG
payupdeadbeat payupdeadbeat 12 minutes ago
You are not alone. Many of us were bamboozled by this skunk.
LVVV
ddls ddls 15 minutes ago
BIEL is a 20-year old junk trading stock. Gone from 50 cents a share in 2005 to .0003 cents a share today.😎

Sales-Track is showing retail sales are down 20% from last years. GO BIEL!😎
BIEL
payupdeadbeat payupdeadbeat 16 minutes ago
Are you forgetting that this "temporarily troubled business" is being "managed" by a Harvard grad? It's only been a decade or so that she has been "working on a recovery plan". That rabbit will be coming out of her hat (or wherever she has to pull it) any day now.  Right Linda?
DBMM
floridaboy floridaboy 16 minutes ago
Progress has been made, little more follow through needed...
MEDH
Lite Lite 18 minutes ago
Capital gains will be a big windfall after GSEs release and stock returns to investors.
FNMA
floridaboy floridaboy 20 minutes ago
TA verification? Attorney letter?
MEDH
floridaboy floridaboy 20 minutes ago
How about a filing?
MEDH
gregcod gregcod 22 minutes ago
Trump has proposed 60% to 1000% increase on chinese imports..Great news! keep them out of our US lithium market, and other precious metals that they control as of now...India has enough people to create a EV market thats big..other countries as well...
IBATF
JPetroInc JPetroInc 24 minutes ago
we’ll spoken and spot on….

SRM didn’t sound too well pleased on the Spaces X 2 call when describing FO and closing the MONI deal. I’m sure RL taking ill and his untimely passing may have clouded their ability to get a better deal than what JL and FO finally ‘gift wrapped’ for the new
MONI SRM
MrSmithLWLG MrSmithLWLG 25 minutes ago
Yes correct but I’m speaking of commercialization.

Here is where they fit together, polarition is a spin off from the lab ETH Zurich, where LWLG was able to prove essentially 4x modulation speed. They are companies of similar maturity. The true problem here is commercialization and sc
LWLG
Ppastis Ppastis 26 minutes ago
Hey Lurket ! Or j... rker !!! Whatever you prefer ...

Always talking talking talking .... full of BS !!!
I give you an advice .....

People who always talk about other people are a sign of weakness of and stupidity !!!

Why ? Because they have nothin
LWLG
Ranb2khz Ranb2khz 29 minutes ago
All Joy No Stress – Rhett Walker (Lyrics)

[yt]fMEDX0IVW34[/yt]

https://www.youtube.com/watch?v=fMEDX0IVW34






•
Frankestin Frankestin 36 minutes ago
Bin releases the kraken!
We will feel a lot of pain.. if good news doesn't come out
WBUY
TRUISM TRUISM 38 minutes ago
NOVEMBER 2024 INVESTOR PRESENTATION PDF

https://irp.cdn-website.com/8deee57f/files/uploaded/2024-11-07_-_Bolt_Projects_Holdings_Investor_2024_Presentation_%282%29.pdf LINK
BSLK
Lurker3 Lurker3 39 minutes ago
Lightwave Logic forward. OMG!! The back-and-forth between the lawyers is incredibl

All thanks to the incredible inside infornation given by KCC.

Oh wait, the deals have been pushed to 2025 and nothing is going to happen this year.
.
LWLG
Lurker3 Lurker3 39 minutes ago
Lightwave Logic forward. OMG!! The back-and-forth between the lawyers is incredibl

All thanks to the incredible inside infornation given by KCC.

Oh wait, the deals have been pushed to 2025 and nothing is going to happen this year.
.
LWLG
chicks0123 chicks0123 41 minutes ago
Good morning CLNVERS 
CLNV
Edward Edward 44 minutes ago
Seem this took many times and I have enough shares too keep doing this!!

I’m locking up shares! So I got an extra 10 million shares for free!!!


I don’t own this stock why would I need to sell?

What. ??????

See post # Post #: 92,960
VXIT
StockItOut StockItOut 50 minutes ago
you're in at $0.02 and you're wahhhh wahhhhing. lol lol lol
XERI
StockItOut StockItOut 52 minutes ago
"Wahhhh wahhhh." right? whining complaining crybaby?
XERI
buysellrepeat buysellrepeat 52 minutes ago
Josh Ploch has been completely scrubbed from the company profile.  The other 2 besides Darnell remain. Would love hear what's happening. Doesn't mean the deal fell apart, under the impression the deal was closed on. 
ATWT

Your Recent History

EU
ALCLS
Cellectis Nom Eo 05
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved